Expanding genotype-phenotype correlations in FOXG1 syndrome: results from a patient registry.

Epilepsy Genotype–phenotype association Movement Disorder Patient registry Rare neurological diseases

Journal

Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602

Informations de publication

Date de publication:
12 06 2023
Historique:
received: 27 01 2023
accepted: 18 05 2023
medline: 14 6 2023
pubmed: 13 6 2023
entrez: 12 6 2023
Statut: epublish

Résumé

We refine the clinical spectrum of FOXG1 syndrome and expand genotype-phenotype correlations through evaluation of 122 individuals enrolled in an international patient registry. The FOXG1 syndrome online patient registry allows for remote collection of caregiver-reported outcomes. Inclusion required documentation of a (likely) pathogenic variant in FOXG1. Caregivers were administered a questionnaire to evaluate clinical severity of core features of FOXG1 syndrome. Genotype-phenotype correlations were determined using nonparametric analyses. We studied 122 registry participants with FOXG1 syndrome, aged < 12 months to 24 years. Caregivers described delayed or absent developmental milestone attainment, seizures (61%), and movement disorders (58%). Participants harbouring a missense variant had a milder phenotype. Compared to individuals with gene deletions (0%) or nonsense variants (20%), missense variants were associated with more frequent attainment of sitting (73%). Further, individuals with missense variants (41%) achieved independent walking more frequently than those with gene deletions (0%) or frameshift variants (6%). Presence of epilepsy also varied by genotype and was significantly more common in those with gene deletions (81%) compared to missense variants (47%). Individuals with gene deletions were more likely to have higher seizure burden than other genotypes with 53% reporting daily seizures, even at best control. We also observed that truncations preserving the forkhead DNA binding domain were associated with better developmental outcomes. We refine the phenotypic spectrum of neurodevelopmental features associated with FOXG1 syndrome. We strengthen genotype-driven outcomes, where missense variants are associated with a milder clinical course.

Sections du résumé

BACKGROUND
We refine the clinical spectrum of FOXG1 syndrome and expand genotype-phenotype correlations through evaluation of 122 individuals enrolled in an international patient registry.
METHODS
The FOXG1 syndrome online patient registry allows for remote collection of caregiver-reported outcomes. Inclusion required documentation of a (likely) pathogenic variant in FOXG1. Caregivers were administered a questionnaire to evaluate clinical severity of core features of FOXG1 syndrome. Genotype-phenotype correlations were determined using nonparametric analyses.
RESULTS
We studied 122 registry participants with FOXG1 syndrome, aged < 12 months to 24 years. Caregivers described delayed or absent developmental milestone attainment, seizures (61%), and movement disorders (58%). Participants harbouring a missense variant had a milder phenotype. Compared to individuals with gene deletions (0%) or nonsense variants (20%), missense variants were associated with more frequent attainment of sitting (73%). Further, individuals with missense variants (41%) achieved independent walking more frequently than those with gene deletions (0%) or frameshift variants (6%). Presence of epilepsy also varied by genotype and was significantly more common in those with gene deletions (81%) compared to missense variants (47%). Individuals with gene deletions were more likely to have higher seizure burden than other genotypes with 53% reporting daily seizures, even at best control. We also observed that truncations preserving the forkhead DNA binding domain were associated with better developmental outcomes.
CONCLUSION
We refine the phenotypic spectrum of neurodevelopmental features associated with FOXG1 syndrome. We strengthen genotype-driven outcomes, where missense variants are associated with a milder clinical course.

Identifiants

pubmed: 37308910
doi: 10.1186/s13023-023-02745-y
pii: 10.1186/s13023-023-02745-y
pmc: PMC10262363
doi:

Substances chimiques

FOXG1 protein, human 0
Nerve Tissue Proteins 0
Forkhead Transcription Factors 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

149

Informations de copyright

© 2023. The Author(s).

Références

Dev Cell. 2009 Apr;16(4):576-87
pubmed: 19386266
Neurol Genet. 2018 Nov 07;4(6):e281
pubmed: 30533527
Contemp Clin Trials. 2015 Jan;40:212-7
pubmed: 25533730
JAMA Neurol. 2017 Jun 1;74(6):727-732
pubmed: 28437535
Hum Mutat. 2018 Sep;39(9):1193-1202
pubmed: 29907980
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Cell Rep. 2013 Mar 28;3(3):931-45
pubmed: 23523356
Epilepsia. 2014 Aug;55(8):1292-300
pubmed: 24836831
Genet Med. 2018 Jan;20(1):98-108
pubmed: 28661489
J Med Genet. 2010 Jan;47(1):59-65
pubmed: 19564653
Cereb Cortex. 2019 Dec 17;29(12):4903-4918
pubmed: 30821834
Neuron. 2012 Jun 21;74(6):1045-58
pubmed: 22726835
J Neurosci. 2002 Aug 1;22(15):6526-36
pubmed: 12151532
Brain. 2020 Apr 1;143(4):1099-1105
pubmed: 32168371
Am J Hum Genet. 2008 Jul;83(1):89-93
pubmed: 18571142
Orphanet J Rare Dis. 2018 Sep 5;13(1):154
pubmed: 30185208
Neurology. 2016 May 10;86(19):1794-800
pubmed: 27029630
J Med Genet. 2011 Jun;48(6):396-406
pubmed: 21441262
J Med Genet. 2010 Jan;47(1):49-53
pubmed: 19578037
Neuron. 2018 Dec 5;100(5):1083-1096.e5
pubmed: 30392794
Int J Environ Res Public Health. 2018 Aug 03;15(8):
pubmed: 30081484
Eur J Hum Genet. 2016 Jun;24(6):871-80
pubmed: 26443267
J Biol Chem. 2003 Jun 6;278(23):20507-13
pubmed: 12657635
Eur J Hum Genet. 2012 Dec;20(12):1216-23
pubmed: 22739344
Stem Cells. 2010 Jul;28(7):1206-18
pubmed: 20506244

Auteurs

Elise Brimble (E)

Invitae, San Francisco, CA, USA. elli.brimble@invitae.com.

Kathryn G Reyes (KG)

Cedars Sinai, Los Angeles, CA, USA.

Kopika Kuhathaas (K)

MGH Institute of Health Professions, Boston, MA, USA.

Orrin Devinsky (O)

NYU Langone Health, New York, NY, USA.

Maura R Z Ruzhnikov (MRZ)

U.S. Food and Drug Administration, Silver Spring, MD, USA.

Xilma R Ortiz-Gonzalez (XR)

Children's Hospital of Philadelphia, Philadelphia, PA, USA.

Ingrid Scheffer (I)

University of Melbourne, Melbourne, Australia.

Nadia Bahi-Buisson (N)

Paris Descartes University/Neckers Hospital, Paris, France.

Heather Olson (H)

Boston Children's Hospital, Boston, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH